

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1. – 2. (Canceled)

3. (Original) An immunogenic composition comprising as an immunogen a long synthetic or recombinant peptide comprising epitopes contained within a MSP-3b peptide (SEQ ID No: 12), a MSP-3c peptide (SEQ ID No: 13), or a MSP-3d peptide (SEQ ID No: 14) and combinations of said peptides.

4. (Currently Amended) A vaccine against malaria comprising ~~a long synthetic or recombinant peptide comprising epitopes contained within a MSP-3b peptide (SEQ ID No: 12), a MSP-3c peptide (SEQ ID No: 13), or a MSP-3d peptide (SEQ ID No: 14) or combinations of said peptides,~~ the long synthetic or recombinant peptide of Claim 3 and a pharmaceutically acceptable carrier.

5. (Currently Amended) The immunogenic composition of claim 3 ~~or the vaccine of claim 4~~, wherein said long synthetic or recombinant peptide further comprises the epitopes contained within a MSP-3a peptide (SEQ ID No: 11).

6. (Currently Amended) The immunogenic composition of claim 3 ~~or the vaccine of claim 4~~, which is formulated for subcutaneous injection.

7. (Original) The immunogenic composition or the vaccine of claim 6, comprising between 3 µg and 100 µg of a long synthetic peptide per injection dose.

8. (Original) The immunogenic composition of claim 3, further comprising Alum and/or Montanide as an adjuvant.

9. (Original) The vaccine of claim 4, wherein said pharmaceutically acceptable carrier comprises Alum and/or Montanide.

10. – 24. (Canceled)

25. (New) The vaccine of claim 4, wherein said long synthetic or recombinant peptide further comprises the epitopes contained within SEQ ID No: 11.

26. (New) The vaccine of claim 4, which is formulated for subcutaneous injection.

27. (New) The immunogenic composition or the vaccine of claim 26, comprising between 3 μg and 100 μg of a long synthetic peptide per injection dose.

SUPPORT FOR THE AMENDMENT

Claims 1, 2, and 10-24 have been canceled.

Claims 4-6 have been amended.

Claims 25-27 have been added.

The amendment of Claims 4-6 is supported by the corresponding claims as originally filed. New Claims 25-27 are supported by original Claims 3-6 and the specification at pages 6-48.

No new matter is believed to have been introduced by virtue of the amendment presented herein.